CoChat

The Effect of Digoxin on Mortality and Morbidity in Patients with Heart Failure

Open access
The Digitalis Investigation Group · 1997 · New England Journal of Medicine

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

BACKGROUND: The role of cardiac glycosides in treating patients with chronic heart failure and normal sinus rhythm remains controversial. We studied the effect of digoxin on mortality and hospitalization in a randomized, double-blind clinical trial. METHODS: In the main trial, patients with a left ventricular ejection fraction of 0.45 or less were randomly assigned to digoxin (3397 patients) or placebo (3403 patients) in addition to diuretics and angiotensin-converting-enzyme inhibitors (median dose of digoxin, 0.25 mg per day; average follow-up, 37 months). In an ancillary trial of patients with ejection fractions greater than 0.45, 492 patients were randomly assigned to digoxin and 496 to placebo. RESULTS: In the main trial, mortality was unaffected. There were 1181 deaths (34.8 percent) with digoxin and 1194 deaths (35.1 percent) with placebo (risk ratio when digoxin was compared with placebo, 0.99; 95 percent confidence interval, 0.91 to 1.07; P=0.80). In the digoxin group, there was a trend toward a decrease in the risk of death attributed to worsening heart failure (risk ratio, 0.88; 95 percent confidence interval, 0.77 to 1.01; P=0.06). There were 6 percent fewer hospitalizations overall in that group than in the placebo group, and fewer patients were hospitalized for worsening heart failure (26.8 percent vs. 34.7 percent; risk ratio, 0.72; 95 percent confidence interval, 0.66 to 0.79; P<0.001). In the ancillary trial, the findings regarding the primary combined outcome of death or hospitalization due to worsening heart failure were consistent with the results of the main trial. CONCLUSIONS: Digoxin did not reduce overall mortality, but it reduced the rate of hospitalization both overall and for worsening heart failure. These findings define more precisely the role of digoxin in the management of chronic heart failure.

Overview

Integrity signals

Registry

Crossref · 10.1056/nejm199702203360801

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

3 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 10 references

Research works printed but not linked: 1

  1. Yusuf S, 1990, Circulation, 82, III

Cited by

See all 3,016

Metadata

Authors
The Digitalis Investigation Group
Affiliations
Mount Sinai Hospital (US)
Corresponding author
The Digitalis Investigation Group
Venue
New England Journal of Medicine
Published
1997-02-20
Volume
336
Issue
8
Pages
525-533
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2945068164
Cited by
3,016
References
10
Citations by year
2026: 74 · 2025: 66 · 2024: 70 · 2023: 82 · 2022: 90 · 2021: 91 · 2020: 88 · 2019: 73 · 2018: 92 · 2017: 102 · 2016: 124 · 2015: 103 · 2014: 96 · 2013: 95 · 2012: 89
FWCI
96.29
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
Keywords
digoxin, chronic heart failure, mortality, hospitalization, worsening heart failure, cardiac glycosides, left ventricular ejection fraction, ACE inhibitors, diuretics
MeSH terms
Aged, Arrhythmias, Cardiac, Cardiotonic Agents, Cardiovascular Diseases, Digoxin, Double-Blind Method, Female, Heart Failure, Hospitalization, Humans, Male, Middle Aged, Stroke Volume, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Effect of Digoxin on Mortality and Morbidity in Patients with Heart Failure. https://app.cochat.ai/papers/10.1056/nejm199702203360801
The paper
The Digitalis Investigation Group. (1997). The Effect of Digoxin on Mortality and Morbidity in Patients with Heart Failure. New England Journal of Medicine. https://doi.org/10.1056/nejm199702203360801

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.